Cargando…

Estimating the cost of diagnosing HIV at birth in Lesotho

BACKGROUND: Infants with HIV infection, particularly those infected in utero, who do not receive antiretroviral therapy (ART) have high mortality in the first year of life. Virologic diagnostic testing is recommended by the World Health Organization between ages 4 and 6 weeks after birth. However, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Tchuenche, M., Gill, M. M., Bollinger, L., Mofenson, L., Phalatse, M., Nchephe, M., Mokone, M., Tukei, V., Tiam, A., Forsythe, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6093690/
https://www.ncbi.nlm.nih.gov/pubmed/30110377
http://dx.doi.org/10.1371/journal.pone.0202420
_version_ 1783347713950089216
author Tchuenche, M.
Gill, M. M.
Bollinger, L.
Mofenson, L.
Phalatse, M.
Nchephe, M.
Mokone, M.
Tukei, V.
Tiam, A.
Forsythe, S.
author_facet Tchuenche, M.
Gill, M. M.
Bollinger, L.
Mofenson, L.
Phalatse, M.
Nchephe, M.
Mokone, M.
Tukei, V.
Tiam, A.
Forsythe, S.
author_sort Tchuenche, M.
collection PubMed
description BACKGROUND: Infants with HIV infection, particularly those infected in utero, who do not receive antiretroviral therapy (ART) have high mortality in the first year of life. Virologic diagnostic testing is recommended by the World Health Organization between ages 4 and 6 weeks after birth. However, adding very early infant diagnosis (VEID) testing at birth has been suggested to enable earlier diagnosis and rapid treatment of in utero infection. We assessed the costs of adding VEID to the standard 6-week testing in Lesotho where coverage of PMTCT services is nearly universal. METHODS: Retrospective cost data were collected at eight health-care facilities in three districts participating in an observational prospective study that included birth testing as well as at the National Reference Laboratory in Lesotho, to investigate the cost-per-infection identified. Extrapolating to the national level, it was possible to estimate the impact of VEID on the identification of HIV-infected infants. RESULTS: The unit cost-per-VEID test in Lesotho in 2015 was $40.50. Major cost drivers were supplies/commodities (46%) and clinical labor (22%). In 2015, 66.3% of cohort study infants born at study facilities underwent VEID; one out of 199 infants had a positive HIV DNA PCR test at birth (0.5% potential in utero infection), yielding a cost of $8,060 per HIV-positive infant identified. Sensitivity analysis showed costs based on Lesotho costing data ranged from $810 to $16,194 per-infected child with varying in utero infection rates from 5% and 0.25%, respectively. With 11,157 HIV-exposed births nationally from pregnant women on PMTCT, 66.3% VEID coverage, and 0.5% in utero infection, 37 infants infected with HIV could have been identified at birth in 2015 and 8 early infant deaths potentially averted with immediate ART compared with waiting for 6-week testing. CONCLUSION: If Lesotho costing data from this pilot study were applied to different epidemic circumstances, the cost-per-infected child identified by adding VEID birth testing to standard 6-week testing was lowest when in utero infection rates were high (when HIV prevalence is high and PMTCT coverage is low).
format Online
Article
Text
id pubmed-6093690
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-60936902018-08-30 Estimating the cost of diagnosing HIV at birth in Lesotho Tchuenche, M. Gill, M. M. Bollinger, L. Mofenson, L. Phalatse, M. Nchephe, M. Mokone, M. Tukei, V. Tiam, A. Forsythe, S. PLoS One Research Article BACKGROUND: Infants with HIV infection, particularly those infected in utero, who do not receive antiretroviral therapy (ART) have high mortality in the first year of life. Virologic diagnostic testing is recommended by the World Health Organization between ages 4 and 6 weeks after birth. However, adding very early infant diagnosis (VEID) testing at birth has been suggested to enable earlier diagnosis and rapid treatment of in utero infection. We assessed the costs of adding VEID to the standard 6-week testing in Lesotho where coverage of PMTCT services is nearly universal. METHODS: Retrospective cost data were collected at eight health-care facilities in three districts participating in an observational prospective study that included birth testing as well as at the National Reference Laboratory in Lesotho, to investigate the cost-per-infection identified. Extrapolating to the national level, it was possible to estimate the impact of VEID on the identification of HIV-infected infants. RESULTS: The unit cost-per-VEID test in Lesotho in 2015 was $40.50. Major cost drivers were supplies/commodities (46%) and clinical labor (22%). In 2015, 66.3% of cohort study infants born at study facilities underwent VEID; one out of 199 infants had a positive HIV DNA PCR test at birth (0.5% potential in utero infection), yielding a cost of $8,060 per HIV-positive infant identified. Sensitivity analysis showed costs based on Lesotho costing data ranged from $810 to $16,194 per-infected child with varying in utero infection rates from 5% and 0.25%, respectively. With 11,157 HIV-exposed births nationally from pregnant women on PMTCT, 66.3% VEID coverage, and 0.5% in utero infection, 37 infants infected with HIV could have been identified at birth in 2015 and 8 early infant deaths potentially averted with immediate ART compared with waiting for 6-week testing. CONCLUSION: If Lesotho costing data from this pilot study were applied to different epidemic circumstances, the cost-per-infected child identified by adding VEID birth testing to standard 6-week testing was lowest when in utero infection rates were high (when HIV prevalence is high and PMTCT coverage is low). Public Library of Science 2018-08-15 /pmc/articles/PMC6093690/ /pubmed/30110377 http://dx.doi.org/10.1371/journal.pone.0202420 Text en © 2018 Tchuenche et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Tchuenche, M.
Gill, M. M.
Bollinger, L.
Mofenson, L.
Phalatse, M.
Nchephe, M.
Mokone, M.
Tukei, V.
Tiam, A.
Forsythe, S.
Estimating the cost of diagnosing HIV at birth in Lesotho
title Estimating the cost of diagnosing HIV at birth in Lesotho
title_full Estimating the cost of diagnosing HIV at birth in Lesotho
title_fullStr Estimating the cost of diagnosing HIV at birth in Lesotho
title_full_unstemmed Estimating the cost of diagnosing HIV at birth in Lesotho
title_short Estimating the cost of diagnosing HIV at birth in Lesotho
title_sort estimating the cost of diagnosing hiv at birth in lesotho
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6093690/
https://www.ncbi.nlm.nih.gov/pubmed/30110377
http://dx.doi.org/10.1371/journal.pone.0202420
work_keys_str_mv AT tchuenchem estimatingthecostofdiagnosinghivatbirthinlesotho
AT gillmm estimatingthecostofdiagnosinghivatbirthinlesotho
AT bollingerl estimatingthecostofdiagnosinghivatbirthinlesotho
AT mofensonl estimatingthecostofdiagnosinghivatbirthinlesotho
AT phalatsem estimatingthecostofdiagnosinghivatbirthinlesotho
AT nchephem estimatingthecostofdiagnosinghivatbirthinlesotho
AT mokonem estimatingthecostofdiagnosinghivatbirthinlesotho
AT tukeiv estimatingthecostofdiagnosinghivatbirthinlesotho
AT tiama estimatingthecostofdiagnosinghivatbirthinlesotho
AT forsythes estimatingthecostofdiagnosinghivatbirthinlesotho